<DOC>
	<DOCNO>NCT00403403</DOCNO>
	<brief_summary>This placebo-controlled , double-blind , multicenter , randomize study preliminary evaluation efficacy safety combine bevacizumab cisplatin ( carboplatin ) etoposide patient previously untreated extensive-stage small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>A Study Bevacizumab Previously Untreated Extensive-Stage Small Cell Lung Cancer ( SALUTE )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically cytologically document small cell carcinoma bronchus , classify extensivestage disease Measurable disease lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy &lt; 12 week Current , recent , planned participation another experimental drug study Ongoing active infection Active malignancy SCLC superficial basal/squamous cell carcinoma within previous 5 year Prior systemic therapy , radiation therapy , surgery SCLC Inadequate bone marrow function , renal function , hepatic function Serum sodium &lt; 120 mg/dL Inadequately controlled hypertension History hypertensive crisis hypertensive encephalopathy New York Heart Association Class II great congestive heart failure History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Known central nervous system disease , except brain metastasis treat wholebrain radiotherapy Significant vascular disease recent peripheral arterial thrombosis within 6 month prior study enrollment History hemoptysis within 4 week prior study enrollment Evidence bleed diathesis coagulopathy absence therapeutic anticoagulation Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , include placement vascular access device , within 7 day prior Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior study enrollment Serious , nonhealing wound , active ulcer , untreated bone fracture Known hypersensitivity component bevacizumab Pregnant ( positive pregnancy test ) lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>SCLC</keyword>
	<keyword>SALUTE</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Avastin</keyword>
</DOC>